US-based Thermo Fisher Scientific is expanding its India footprint with new R&D and customer facilities to tap into the country’s growing biosimilars and research sector. The move aims to support India’s position as a key hub for pharmaceutical innovation and exports.
Thermo Fisher Scientific is significantly deepening its operational footprint in India, focusing on infrastructure to support the country's rapidly evolving biopharmaceutical, semiconductor, and clean energy sectors. As a global leader in laboratory equipment, the company is intensifying its focus on the Indian market, which has emerged as a critical growth engine within its Asia-Pacific and Middle East operations.
Key to this expansion are strategic infrastructure developments aimed at strengthening local research and development capabilities. The company has established a specialized bioprocess design and customer experience center in Hyderabad’s Genome Valley. Additionally, it has invested approximately ₹160 crore to expand its R&D Centre of Excellence in Bengaluru. These facilities are designed to provide local scientists with advanced training and technical support on sophisticated laboratory instrumentation and automation systems.
This capital investment comes at a time when India is positioning itself as a major global hub for biopharmaceutical innovation. With the Indian biosimilars market projected to grow significantly to $4.2 billion by 2030, domestic pharmaceutical companies are increasingly pivoting toward high-value innovative medicines. Thermo Fisher’s expansion is strategically aligned to capture this shift, as local manufacturers require advanced equipment for research, development, and high-quality production to meet both domestic and export demand.
On the global front, the company’s parent entity, listed on the New York Stock Exchange, continues to show strong financial momentum. In its second quarter of 2026, the global firm reported revenue of $11.99 billion, marking a 10% increase compared to the previous year. The company is also streamlining its portfolio, having recently completed the $1.075 billion divestiture of its microbiology business to Astorg on August 12, 2026. This move reflects a broader corporate strategy of focusing capital allocation toward high-growth areas like bioprocessing and laboratory technology.
While the expansion signals confidence in the Indian market, the company faces inherent business risks. Like many global players in the scientific instrumentation space, Thermo Fisher remains exposed to global supply chain pressures that can impact the distribution and delivery of specialized equipment. Furthermore, the company’s growth model is heavily reliant on mergers and acquisitions, which carries the risk of integration challenges and the need to justify valuations of acquired technologies.
In India, the company must also navigate the evolving regulatory landscape of the pharmaceutical and biologics sector. Investors and industry watchers will track the utilization of these new facilities and the company's ability to maintain its market share against both global and emerging domestic competitors as the biopharmaceutical landscape matures.